TY - JOUR
T1 - Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk
T2 - A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort
AU - Obón-Santacana, Mireia
AU - Freisling, Heinz
AU - Peeters, Petra H.
AU - Lujan-Barroso, Leila
AU - Ferrari, Pietro
AU - Boutron-Ruault, Marie Christine
AU - Mesrine, Sylvie
AU - Baglietto, Laura
AU - Turzanski-Fortner, Renee
AU - Katzke, Verena A.
AU - Boeing, Heiner
AU - Quirós, J. Ramón
AU - Molina-Portillo, Elena
AU - Larrañaga, Nerea
AU - Chirlaque, María Dolores
AU - Barricarte, Aurelio
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Travis, Ruth C.
AU - Merritt, Melissa A.
AU - Gunter, Marc J.
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Naska, Androniki
AU - Palli, Domenico
AU - Sieri, Sabina
AU - Tumino, Rosario
AU - Fiano, Valentina
AU - Galassom, Rocco
AU - Bueno-de-Mesquita, H. B.
AU - Onland-Moret, N. Charlotte
AU - Idahl, Annika
AU - Lundin, Eva
AU - Weiderpass, Elisabete
AU - Vesper, Hubert
AU - Riboli, Elio
AU - Duell, Eric J.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95%CI: 0.49-1.48; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI<25 vs. ≥25 kg m-2, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
AB - Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95%CI: 0.49-1.48; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI<25 vs. ≥25 kg m-2, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
KW - Acrylamide
KW - Endometrial cancer
KW - EPIC
KW - Glycidamide
KW - Hemoglobin adduct
UR - http://www.scopus.com/inward/record.url?scp=84946059566&partnerID=8YFLogxK
U2 - 10.1002/ijc.29853
DO - 10.1002/ijc.29853
M3 - Article
C2 - 26376083
AN - SCOPUS:84946059566
SN - 0020-7136
VL - 138
SP - 1129
EP - 1138
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 5
ER -